Prothena recently joined the Rare Disease Company Coalition, a coalition of companies dedicated to discovering, developing, and delivering rare disease treatments for the patients we collectively serve.

“We are happy to welcome Prothena to the Coalition; they join us in our work to advocate for policies that enable positive changes to be realized for the rare disease community,” says RDCC Executive Director, Amanda Malakoff.

Prothena SVP for Corporate Affairs Eric Endicott joined RDCC in Washington, D.C. during Rare Disease Week on capitol hill to help drive awareness and education of policy makers. Prothena is grateful to be involved with this alliance dedicated to improving outcomes for the rare disease community, including those living with amyloidosis. We look forward to a collaborative partnership aimed at shining a light on rare diseases.

“The range of organs that can be affected by amyloidosis poses a broad challenge for the biotech industry. This rare disease deserves the industry’s focused attention, and to make true progress, we all must come together as one. Prothena is pleased to play a role in this effort,” shares Prothena Director for Patient Advocacy and Professional Relations, Karen Ross.

As with any alliance we are a part of, we welcome the opportunity to work alongside other biopharmaceutical corporations to expedite solutions for patients and their families. Everything we do remains steadfast in our goal of reducing the societal toll these diseases will inevitably take.